Postoperative complications of coronary artery bypass grafting: a narrative review on pathophysiology, management strategies, and the emerging role of artificial intelligence
Abstract
Background and objective: Coronary artery bypass grafting (CABG) remains a vital treatment option for high-risk patients with advanced coronary artery disease, especially those with multivessel disease, extensive left main disease, or refractory angina. While CABG effectively lowers long-term mortality and morbidity, it is still associated with many postoperative complications that can hinder recovery and affect quality of life. This review aims to thoroughly explore risk factors, prevention, and management strategies of major postoperative complications after CABG, categorized by physiological systems.
Methods: A comprehensive literature review was conducted on PubMed and Google Scholar from January 1, 2005, to August 6, 2025, without applying filters, but only including English-language publications, to gather a wide range of studies. Full texts were chosen based on set criteria, followed by a qualitative analysis to identify common themes, results, and gaps.
Key content and findings: Post-CABG complications span neurological, cardiac, pulmonary, renal, gastrointestinal/hepatobiliary, infectious, endocrine, and psychosocial domains. Across systems, consistently identified significant risk factors include advanced age, diabetes, renal dysfunction, prolonged cardiopulmonary bypass time, prior stroke, chronic obstructive pulmonary disease (COPD), and impaired left ventricular (LV) function. Effective preventive strategies included optimized glycemic control, early…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.